Canopy Growth Corp vs Core and Main Inc — how do they compare? Canopy Growth Corp trades at $1 (market cap $421.10M), while Core and Main Inc trades at $46.18 (market cap $8.73B). The key difference: Core and Main Inc is far larger — about 20.7× Canopy Growth Corp's market cap. Which is the better fit depends on your goals.
| CGC | CNM | |
|---|---|---|
Market Cap | $421.10M | $8.73B |
Sector | Health | Technology |
52-Week High | $1.92 | $66.98 |
52-Week Low | $0.86 | $42.37 |
Enterprise Value | $378.55M | $11.02B |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $1.025, up 7.66% with bullish technical signals. The company shows improving fundamentals with Q1 2027 revenue growth of 13% and narrowing losses. Recent acquisitions and cost-cutting initiatives support expansion in medical and European cannabis markets. The stock trades below book value (P/B 0.86) while maintaining a P/S ratio of 1.71.
CGC presents a high-risk turnaround opportunity with improving balance sheet metrics and positive revenue momentum. However, persistent negative earnings and cash flow challenges require careful monitoring. Analyst sentiment remains divided with 33% buy ratings, reflecting the speculative nature of cannabis sector investments amid ongoing regulatory uncertainty.
Core & Main (CNM) trades at $45.9, down 0.86% today, with a bullish technical signal despite near-term pressure. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.57 beating expectations of $0.534. Revenue reached $7.44B in 2025 with 5.87% net margin, while analyst consensus remains positive with 57% buy ratings. Recent news highlights institutional activity including California State Teachers Retirement System increasing its position by 22.3% in Q1 2026.
CNM presents a compelling investment case with robust profitability (23.73% ROE) and improving cash flow trends, though elevated debt levels and competitive pressures warrant caution. The stock's current valuation at 19.76 P/E appears reasonable given growth prospects, with technical support at $46 providing downside protection. Upside potential exists if the company maintains its earnings beat streak and executes on FY26 guidance of $7.8-7.9B revenue.
Trailing returns across standard periods
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →